Smith Group Asset Management’s Acceleron Pharma XLRN Stock Holding History

Smith Group Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,350	Closed	-$129K	–	343
2020 Q2	$129K	Sell	1,350 -20	-1%	-$1.93K	0.01%	183
2020 Q1	$123K	Hold	1,370	–	–	0.01%	198
2019 Q4	$73K	Hold	1,370	–	–	﹤0.01%	256
2019 Q3	$54K	Buy	1,370 +530	+63%	+$23K	﹤0.01%	274
2019 Q2	$35K	Hold	840	–	–	﹤0.01%	301
2019 Q1	$39K	Sell	840 -2,700	-76%	-$119K	﹤0.01%	318
2018 Q4	$154K	Buy	+3,540	New	+$177K	0.01%	260
2016 Q3	–	Sell	-5,940	Closed	-$202K	–	501
2016 Q2	$202K	Buy	+5,940	New	+$193K	0.01%	259
2015 Q2	–	Sell	-23,090	Closed	-$879K	–	441
2015 Q1	$879K	Sell	23,090 -1,800	-7%	-$71.6K	0.03%	179
2014 Q4	$970K	Sell	24,890 -2,510	-9%	-$87.5K	0.03%	183
2014 Q3	$828K	Buy	+27,400	New	+$772K	0.03%	183

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Smith Group Asset Management's XLRN Position: Q3 2020 in Review

Smith Group Asset Management sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 1,350 shares — an estimated $129K sold.

Smith Group Asset Management first reported a position in XLRN in Q3 2014 and held it in 11 quarters. The position peaked at $970K in Q4 2014. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

Smith Group Asset Management reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
Smith Group Asset Management sold 1,350 Acceleron Pharma shares in Q3 2020, an estimated $129K.
Smith Group Asset Management first reported a position in Acceleron Pharma in Q3 2014 and held it in 11 quarters.
Smith Group Asset Management's Acceleron Pharma position peaked at $970K in Q4 2014.
238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Smith Group Asset Management's 13F filing for Q3 2020, filed 4 Nov 2020.